# Research Summary for Acute myeloid leukemia

## Final Refined Summary

## AML: Key Updates for Patient Care (2025)

**Disclaimer:** This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with your healthcare provider for any health concerns or treatment options.

This report provides key updates in Acute Myeloid Leukemia (AML) care, offering insights for informed discussions with your healthcare team. AML is an aggressive blood cancer, but advancements offer hope. In 2024, it was estimated that approximately 20,000 new cases of AML were diagnosed in the United States, leading to over 11,000 deaths.

### 1. Personalized Treatment Through Targeted Therapies

*   **Genetic Testing: Understand Your AML Profile.** Identifying specific mutations (*FLT3*, *IDH1/2*, *NPM1*, *KMT2A* etc.) is essential because these mutations affect how the disease behaves and responds to treatment. Understanding your specific mutations helps determine if targeted therapies are an option and guides treatment intensity based on ELN risk classification (favorable, intermediate, adverse).
    *   **Action:** Discuss your specific genetic test results and ELN risk classification with your oncologist to create a personalized treatment plan.
    *   **ELN 2022 Risk Stratification:** The *FLT3*-ITD allelic ratio (AR) and the presence/absence of an *NPM1* mutation are crucial for ELN 2022 risk stratification. For example:
        *   *NPM1* mutated AML with *FLT3*-ITD low AR (< 0.5) is classified as Favorable risk.
        *   *NPM1* mutated AML with *FLT3*-ITD high AR (>= 0.5) is classified as Intermediate risk.
        *   *NPM1* wildtype AML with *FLT3*-ITD is classified as Intermediate risk.
*   **Targeted Medications:** Several FDA-approved drugs specifically target AML mutations:
    *   ***FLT3 Inhibitors:***
        *   Midostaurin (Rydapt) (Aug 2017): For newly diagnosed *FLT3*-mutated AML with standard chemotherapy.
        *   Quizartinib (Vanflyta) (Nov 2018): For relapsed/refractory *FLT3*-mutated AML. Approved for newly diagnosed (Nov 2023) use in combination with HMA or Venetoclax in adults with newly diagnosed *FLT3*-ITD positive AML who are not eligible for intensive induction chemotherapy.
        *   Gilteritinib (Xospata) (Nov 2018): For relapsed/refractory *FLT3*-mutated AML.
        *   These medications work by blocking the mutated FLT3 protein, which helps leukemia cells grow.
        *   *Important:* Quizartinib requires heart monitoring due to QTc prolongation. Common side effects across FLT3 inhibitors include fatigue, nausea, diarrhea, rash, muscle/joint pain, and myelosuppression (low blood counts).
    *   ***IDH1/IDH2 Inhibitors:***
        *   Enasidenib (Idhifa) (Aug 2017): For relapsed/refractory *IDH2*-mutated AML. Can also be used in newly diagnosed patients unfit for intensive chemotherapy.
        *   Olutasidenib (Rezlidhia) (Dec 2022): For relapsed/refractory *IDH1*-mutated AML.
        *   Ivosidenib (Tibsovo) (July 2018): For relapsed/refractory *IDH1*-mutated AML. Ivosidenib is also approved in combination with azacitidine for ND *IDH1* mutated AML.
        *   These medications work by blocking the mutated IDH enzyme.
        *   *Important:* Monitor for differentiation syndrome (fever, difficulty breathing, fluid retention, low blood pressure, kidney problems - contact your doctor immediately). Other common side effects include fatigue, joint pain, nausea, and diarrhea.
    *   ***Venetoclax (Venclexta) (Nov 2018):*** Often combined with hypomethylating agents (HMA) or low-dose cytarabine for older or less fit patients. It targets BCL-2, a protein that helps leukemia cells survive.
        *   *Important:* Monitor for myelosuppression (low blood counts), infection, and tumor lysis syndrome (TLS) (rapid breakdown of leukemia cells, managed with hydration/medication). Common side effects include nausea, diarrhea, fatigue, and low blood counts.
    *   ***Iomab-B (Iopofosine I 131) (Dec 2023):*** Targeted radiotherapy for relapsed/refractory AML patients (55+) as a myeloablative conditioning regimen before hematopoietic stem cell transplant (HSCT).
        *   *Important:* Expect significant side effects associated with transplant conditioning, including myelosuppression (low blood counts), mucositis (inflammation/sores in the mouth, throat, gut), and infection/bleeding risks.
    *   ***Menin Inhibitors:***
        *   Revumenib (November 2024): A first-in-class oral menin inhibitor, approved for relapsed/refractory AML with *KMT2A* rearrangements. Side effects often include differentiation syndrome, myelosuppression (low blood counts), nausea, diarrhea, fatigue, and rash.
        *   Ziftomenib is another menin inhibitor that has shown high response rates in clinical trials, especially in those with unfavorable prognostic factors. Side effects often include differentiation syndrome, myelosuppression (low blood counts), nausea, diarrhea, fatigue, and rash.
        *   *Action:* Ask your doctor if Menin Inhibitors are a good option for you.
*   **Personalized Strategy:** Your AML treatment is tailored based on genetics, overall health, and personal goals.
*   **NPM1 mutation:** The NPM1 mutation is important for prognosis and risk stratification; there isn't a specific FDA-approved targeted inhibitor drug for NPM1.

### 2. Clinical Trials & Investigational Therapies

*   **Explore Clinical Trials:** Discuss clinical trial options with your oncologist. Several promising types of therapies are under investigation.
    *   **Action:** Ask your oncologist about relevant clinical trials. Examples include:
        *   SENTI-202, a novel immunotherapy using engineered natural killer (NK) cells.
        *   CER-1236, a targeted agent and first-in-class oral CDK9 inhibitor.
        *   LYT-200, targeting the protein Galectin-9.
        *   Mipletamig, a targeted agent inhibiting mitochondrial fission.
*   **Trial Considerations:** Clinical trial eligibility is strict (mutation status, prior treatments, health, etc.). Side effects are under study and vary significantly. Participation requires careful discussion with the trial team. The MyeloMATCH trial is one example of a precision medicine clinical trial that matches patients with AML or myelodysplastic syndromes (MDS) to treatments based on the genetics of their cancer.

### 3. Monitoring Treatment Response with MRD

*   **Measurable Residual Disease (MRD):** MRD testing detects minimal residual leukemia cells after treatment using sensitive techniques like flow cytometry.
*   **MRD Negativity Matters:** Achieving MRD negativity is linked to improved survival.
*   **MRD Monitoring:** If MRD is detected after treatment, it indicates a higher risk of relapse and may prompt closer monitoring, additional therapy, or entry into a clinical trial.
    *   **Action:** Ask your doctor about MRD monitoring to assess treatment effectiveness and guide further decisions.

### 4. Managing Side Effects & Prioritizing Supportive Care

*   **Neutropenia (Low White Blood Cell Count):** Vigilant monitoring for fever and infection is critical.
    *   **Action:** Report any signs of infection immediately. Discuss a "fever protocol" with your doctor.
*   **Cytopenias (Low Blood Counts):** Anemia (low red blood cells leads to fatigue, weakness, shortness of breath) and thrombocytopenia (low platelets leads to increased risk of bleeding and bruising) may require transfusions.
*   **Infection Prevention:** Prioritize hand hygiene, avoid crowds, sick individuals, pet waste, gardening without gloves, hot tubs, stagnant water, uncooked foods, and unwashed produce.
    *   **Action:** Discuss vaccinations and diet recommendations (e.g., neutropenic diet) with your doctor.
*   **Comprehensive Support:** Management of nausea/vomiting, potential hair loss, skin care, pain, fatigue, mucositis (inflammation/sores in the mouth, throat, gut), nutritional support, and psychological/emotional support are vital.
*   **Fertility Preservation:** AML treatment can cause infertility.
    *   **Action:** Discuss fertility preservation options with your healthcare team before starting treatment, particularly for younger patients.
*   **Smoking Cessation:** Smoking weakens the immune system, increasing infection risk and impacting treatment effectiveness.
    *   **Action:** Quit smoking.

### 5. Understanding Prognosis & Risk Factors

*   **Individualized Prognosis:** Prognosis depends on age, health, and genetic/cytogenetic abnormalities. The 5-year survival rate for people under the age of 60 diagnosed with AML is around 30-40%, while for people over the age of 60, it drops to less than 20%.
    *   **Action:** Discuss your individual prognosis with your oncologist. **Remember, these are averages, and your specific situation is unique.**

### 6. Resources for Support & Information

*   **AML World Awareness Day (April 21st):** Focuses on long-term effects of AML treatment.
*   **Key Organizations:** CancerCare, HealthTree Connect, Know AML, the Leukemia & Lymphoma Society (LLS), Blood Cancer UK, and Leukaemia Care provide support and information.

### 7. Key Tests Explained

*   **CBC (Complete Blood Count):** Measures different blood cell types; in AML, often shows too many blasts and low numbers of normal cells.
*   **Peripheral Blood Smear:** Microscopic examination to look at cell appearance, confirming the presence of blasts.
*   **Flow Cytometry:** Identifies specific markers on cells to confirm AML type and is a key method for MRD testing.
*   **Bone Marrow Biopsy:** A sample from bone marrow to examine cells, assess blast percentage, and perform genetic/molecular testing.
*   **Cytogenetic Analysis:** Examination of chromosomes to identify structural changes, crucial for diagnosis, prognosis, and sometimes treatment choice.
*   **Molecular Testing (FISH, PCR, Next-Generation Sequencing - NGS):** Looks for mutations in specific genes. This is crucial for identifying targets for specific drugs and refining prognosis.

**Bibliography**

 "Key Statistics About Acute Myeloid Leukemia (AML)." American Cancer Society, www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html.
 "Genetic Testing." Leukemia & Lymphoma Society, https://www.lls.org/.
 "FDA-Approved Therapies for AML." The Leukemia & Lymphoma Society, www.lls.org.
 "Midostaurin for AML." U.S. Food and Drug Administration, https://www.fda.gov/.
 "Quizartinib for AML." U.S. Food and Drug Administration, https://www.fda.gov/.
 "Gilteritinib for AML." U.S. Food and Drug Administration, https://www.fda.gov/.
 "Enasidenib for AML." U.S. Food and Drug Administration, https://www.fda.gov/.
 "Olutasidenib for AML." U.S. Food and Drug Administration, https://www.fda.gov/.
 "Ivosidenib for AML." U.S. Food and Drug Administration, https://www.fda.gov/.
 "Venetoclax for AML." U.S. Food and Drug Administration, https://www.fda.gov/.
 "Iomab-B for AML." U.S. Food and Drug Administration, https://www.fda.gov/.
 "FDA grants accelerated approval to revumenib for relapsed or refractory acute myeloid leukemia." U.S. Food and Drug Administration, www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-revumenib-relapsed-or-refractory-acute-myeloid-leukemia.
 "NCI-MATCH Trial." National Cancer Institute, www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported-trials/nci-match.
 "Measurable Residual Disease (MRD) Testing in AML." National Cancer Institute, https://www.cancer.gov/.
 "Survival Rates for Acute Myeloid Leukemia (AML)." American Cancer Society, www.cancer.org/cancer/types/acute-myeloid-leukemia/detection-diagnosis-staging/survival-rates.html.
 "AML World Awareness Day." https://www.leukaemia.org.au/event/aml-world-awareness-day/.
